Regenerative Biologics for Youngstown Medspas and Dermatology Practices

How medspas and dermatology practices vet a supplier

Because medspas in this category operate under physician supervision, vendor qualification usually starts with confirming that the supervising physician's name is on the account and that ordering runs through a licensed entity rather than an individual aesthetician. Dermatology and plastic surgery practices tend to add a second step: requesting the full ingredient disclosure for any exosome product before it goes in front of a medical director for sign-off.

Both groups generally want to see the lot certificate of analysis and, for Wharton's jelly products, the donor eligibility summary before a first order is placed.

NPI verification keeps ordering restricted to licensed accounts

Precision Biologics requires a National Provider Identifier to open an account and checks it against the public NPPES registry. A medspa ordering under physician supervision provides the supervising physician's NPI as part of that process.

This keeps the product line limited to licensed clinics, physicians and medspas, rather than direct consumer sales, consistent with how these products move through the industry.

Shipping and storage for aesthetic practices

Cryopreserved Wharton's jelly formats, including Bio PRP Jelly, Bio Flex and Bio Flow, ship overnight on dry ice in validated containers and require storage at -80 degrees Celsius once received. Lyophilized formats, including Bio DPM and the exosome lines, are shelf-stable and easier to hold between orders for practices without ultra-low freezer capacity on site.

Documentation, medical director sign-off and account setup

Whether a specific aesthetic use fits a practice's regulatory posture is something to confirm with the Ohio medical board and the practice's own counsel rather than with a supplier. Precision Biologics' role is to make the documentation available for that review.

To open an account, submit the supervising physician's NPI and practice license information; our team shares the relevant certificates of analysis and ingredient disclosures and can set up a peer-to-peer call focused on documentation, not technique.

FDA has stated there are no FDA-approved exosome products. Exosome products are generally regulated as biologic drugs under section 351 of the Public Health Service Act, not as 361 HCT/Ps. Purchase and clinical use decisions belong to the physician with their own regulatory counsel.

These products are not FDA approved or licensed for any disease or condition. Information is for licensed healthcare professionals and is not medical or legal advice.